EyePoint Pharmaceuticals | 4:持股變動聲明-董事 GUYER DAVID R
EyePoint Pharmaceuticals | 4:持股變動聲明-高管 Elston George
EyePoint Pharmaceuticals | 8-K:重大事件
EyePoint Pharmaceuticals | 4:持股變動聲明-董事 GUYER DAVID R
EyePoint Pharmaceuticals | 144:擬議出售證券
EyePoint Pharmaceuticals | 10-Q:季度報表
EyePoint Pharmaceuticals | 4:持股變動聲明-股東 Cormorant Asset Management, LP
EyePoint Pharmaceuticals | 8-K:EyePoint Pharmicals公佈2024年第一季度財務業績並重點介紹最近的公司發展
EyePoint Pharmaceuticals | 8-K:重大事件
EyePoint Pharmaceuticals | SC 13G/A:超過5%持股股東披露文件(修正)-Adage Capital Management, L.P.(9.90%),Robert Atchinson(9.90%)等
EyePoint Pharmaceuticals | SC 13G:超過5%持股股東披露文件-Adage Capital Management, L.P.(10.35%),Robert Atchinson(10.35%)等
EyePoint Pharmaceuticals | DEFA14A:其他
EyePoint Pharmaceuticals | DEF 14A:股東委託書決議
EyePoint Pharmaceuticals | 3:首次持股聲明-股東 Adage Capital Management, L.P.
EyePoint Pharmaceuticals | 4:持股變動聲明-股東 Cormorant Asset Management, LP
EyePoint Pharmaceuticals | 4:持股變動聲明-高管 Paggiarino Dario A.
EyePoint Pharmaceuticals | 10-K:年度報表
EyePoint Pharmaceuticals | 8-K:EyePoint Pharmaceuticals公佈了2023年第四季度和全年財務業績,並重點介紹了最近的公司發展
EyePoint Pharmaceuticals | 4:持股變動聲明-高管 Ribeiro Ramiro
EyePoint Pharmaceuticals | 3:首次持股聲明-高管 Ribeiro Ramiro
暫無數據